Local venous response to N-desethylamiodarone in humans

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 1, 2000, Pages 22-31

  Grossmann, Matthias ^a   Dobrev, Dobromir ^b   Himmel, Herbert M ^b   Kirch, Wilhelm ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA TOCOPHEROL; CALCIUM; CYCLOOXYGENASE 1; DEETHYLAMIODARONE; HYDROCORTISONE; N(G) METHYLARGININE; PHENYLEPHRINE; PROSTAGLANDIN F2 ALPHA;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CATTLE; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VEIN DILATATION;

EID: 0033950126     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.103822     Document Type: Article

References (46)

1. 1. Cleland JG, Dargie HJ, Findlay IN, Wilson JT. Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. Br Heart J 1987;57:436-45.
2. 2. Hamer AW, Arkles LB, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol 1989;14:1768-74.
3. 3. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997; 96:2823-9.
4. 4. Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989;118:433-40.
5. 5. Stevenson WG. Mechanisms and management of arrhythmias in heart failure. Curr Opin Cardiol 1995;10:274-81.
6. 6. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhythmic effects: a review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-35.
7. 7. Singh BN, Venkatesh N, Nademanee K, Josephson MA, Kannan R. The historical development, cellular electrophysiology and pharmacology of amiodarone. Prog Cardiovasc Dis 1989;31:249-80.
8. 8. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29.
9. 9. Singh BN, Jewitt DE, Downey JM, Kirk ES, Sonnenblick EH. Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary haemodynamics and on cardiac intracellular potentials. Clin Exp Pharmacol Physiol 1976;3:427-42.
10. 10. Nademanee K, Hendrickson J, Kannan R, Singh BN. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia. Am Heart J 1982;103: 950-9.
11. 11. Wellens HJ, Brugada P, Abdollah H, Dassen WR. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation 1984;69:120-4.
12. 12. Heger JJ, Prystowsky EN, Zipes DP. Relationships between amiodarone dosage, drug concentrations, and adverse side effects. Am Heart J 1983;106:931-5.
13. 13. Charlier R, Deltour G, Baudine A, Chaillet F. Pharmacology of amiodarone, and anti-anginal drug with a new biological profile. Arzneimittelforschung 1968;18:1408-17.
14. 14. Kosinski EJ, Albin JB, Young E, Lewis SM, LeLand OS Jr. Hemodynamic effects of intravenous amiodarone. J Am Coll Cardiol 1984;4:565-70.
15. 15. Grossmann M, Dobrev D, Kirch W. Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo. Clin Pharmacol Ther 1998;64:302-11.
16. 2+ associated with cellular injury to human pulmonary artery endothelial cells. Toxicol Appl Pharmacol 1990;103:156-64.
17. 17. Hageluken A, Nurnberg B, Harhammer R, Grunbaum L, Schunack W, Seifert R. The class III antiarrhythmic drug amiodarone directly activates pertussis toxin-sensitive G proteins. Mol Pharmacol 1995;47:234-40.
18. 18. Himmel HM, Whorton AR, Strauss HC. Intracellular calcium, currents, and stimulus-response coupling in endothelial cells. Hypertension 1993;21:112-27.
19. 2+ transient in vascular smooth muscle cells in coculture. J Biol Chem 1996;271: 5647-55.
20. 20. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994;38:199-204.
21. 21. Pan HY, Hoffman BB, Pershe RA, Blaschke TF. Decline in beta adrenergic receptor-mediated vascular relaxation with aging in man. J Pharmacol Exp Ther 1986;239:802-7.
22. 22. Haefeli WE, Gumbleton M, Benet LZ, Hoffman BB, Blaschke TF. Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. Clin Pharmacol Ther 1992;52:590-6.
23. i and membrane currents in single bovine aortic endothelial cells. Am J Physiol 1994; 267:C1338-50.
24. 24. Meyer zu Heringdorf D, van Koppen CJ, Windorfer B, Himmel HM, Jakobs KH. Calcium signalling by G protein-coupled sphingolipid receptors in bovine aortic endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 1996;354:397-403.
25. 25. Bedarida GV, Kim D, Blaschke TF, Hoffman BB. Characterization of an inhibitor of nitric oxide synthase in human hand veins. Horm Metab Res 1994;26:109-12.
26. 26. Bedarida GV, Bushell E, Haefeli WE, Blaschke TF, Hoffman BB. Responsiveness to bradykinin in veins of hypercholesterolemic humans. Circulation 1993;88:2754-61.
27. 27. Plomp TA, Engels M, Robles de Medina EO, Maes RA. Simultaneous determination of amiodarone and its major metabolite desethylamiodarone in plasma, urine and tissues by high-performance liquid chromatography. J Chromatogr 1983;273:379-92.
28. 28. Daoud EG, Man KC, Horwood L, Morady F, Strickberger SA. Relation between amiodarone and desethylamiodarone plasma concentrations and ventricular defibrillation energy requirements. Am J Cardiol 1997;79:97-100.
29. 29. Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 1991;31: 1061-9.
30. 30. Kodavanti PR, Pentyala SN, Yallapragada PR, Desaiah D. Amiodarone and desethylamiodarone increase intrasynaptosomal free calcium through receptor mediated channel. Naunyn Schmiedebergs Arch Pharmacol 1992;345: 213-21.
31. 31. Vanhoutte PM. Role of calcium and endothelium in hypertension, cardiovascular disease, and subsequent vascular events. J Cardiovasc Pharmacol 1992;19:S6-10.
32. 32. Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J 1997;18:E19-29.
33. 33. Moncada S, Higgs EA, Vane JR. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet 1977;1: 18-20.
34. 34. Futamura Y. Effect of amiodarone on release of cytokines from mouse alveolar macrophages pretreated with eicosapentaenoic acid. Jpn J Pharmacol 1995;69:335-41.
35. 35. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation 1997;96: 1386-9.
36. 36. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms [editorial]. Clin Sci (Colch) 1998; 94:557-72.
37. 37. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997;96:3042-7.
38. 38. Martin A, Wu D, Baur W, Meydani SN, Blumberg JB, Meydani M. Effect of vitamin E on human aortic endothelial cell responses to oxidative injury. Free Radic Biol Med 1996;21:505-11.
39. 39. Evstigneeva RP, Volkov IM, Chudinova VV. Vitamin E as a universal antioxidant and stabilizer of biological membranes. Membr Cell Biol 1998;12:151-72.
40. 40. Rosen P, Du X, Tschope D. Role of oxygen derived radicals for vascular dysfunction in the diabetic heart: prevention by alpha-tocopherol? Mol Cell Biochem 1998; 188:103-11.
41. 41. Huang A, Sun D, Kaley G, Koller A. Superoxide released to high intra-arteriolar pressure reduces nitric oxide-mediated shear stress-and agonist-induced dilations. Circ Res 1998;83:960-5.
42. 42. Rodriguez-Martinez MA, Garcia-Cohen EC, Baena AB, Gonzalez R, Salaices M, Marin J. Contractile responses elicited by hydrogen peroxide in aorta from normotensive and hypertensive rats. Endothelial modulation and mechanism involved. Br J Pharmacol 1998;125:1329-35.
43. 2-induced contraction in pulmonary artery. Am J Physiol 1997;272:H2686-92.
44. 44. Ruch RJ, Bandyopadhyay S, Somani P, Klaunig JE. Evaluation of amiodarone free radical toxicity in rat hepatocytes. Toxicol Lett 1991;56:117-26.
45. 45. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins - 1. Br J Clin Pharmacol 1994;38:181-96.
46. 46. Aellig WH. Clinical pharmacology, physiology and pathophysiology of superficial veins - 2. Br J Clin Pharmacol 1994;38:289-305.